-
Mashup Score: 0Analyzing the Role of BTK Inhibitors and Combination Therapies in the Frontline Treatment of Patients With CLL - 6 month(s) ago
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, John Allan, MD, analyzes the role of BTK inhibitors and combination therapies in the frontline treatment of patients with chronic lymphocytic leukemia.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0HOME - Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors - 6 month(s) ago
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the…
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Pirtobrutinib Demonstrates Durable Efficacy and Safety Among Patients With Covalent BTK Inhibitor Pretreated R/R MCL - 6 month(s) ago
Kami J. Maddocks, MD, analyzes the updated results of the BRUIN trial on the efficacy and safety of pirtobrutinib among patients with high-risk heavily pretreated R/R mantle cell lymphoma with prior covalent BTK inhibitor therapy.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
LINC 23 – We are joined by Principal Investigator, Dr Sahil Parikh (Columbia University Irving Medical Center, US) to discuss Abbott’s LIFE-BTK Randomised Controlled Trial. The
Source: www.radcliffevascular.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1article - 7 month(s) ago
IntroductionChronic lymphocytic leukemia (CLL) is the most common type of leukemia affecting adults in western countries, mainly affecting older adults, with a median age at diagnosis of 72 years;1,2 its incidence and prevalence are expected to further increase in the short-term, proportionally increasing with the aging of the population.Chemo-immunotherapy regimens (eg, fludarabine…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Chemo-immunotherapy regimens have been the standard of care for #ChronicLymphocyticLeukemia. Yet, novel targeted agents—like #BTK and B-cell lymphoma-2 inhibitors—offer therapeutic options with higher #efficacy and personalized treatment. Learn more: https://t.co/BOKL4lNyrg #CLL https://t.co/2eC26XEqnd
-
-
Mashup Score: 0Analyzing Mechanisms of Pirtobrutinib Resistance Among Patients With CLL Pre-Treated With a Covalent BTK Inhibitor - 7 month(s) ago
At the 2023 EHA Congress, Jennifer Brown, MD, presented study findings on mechanisms of resistance to pirtobrutinib among patients with chronic lymphocytic leukemia pre-treated with a covalent BTK inhibitor.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Here, Jennifer Brown, MD, presents results from the Bruin study on mechanisms of resistance to #pirtobrutinib among patients with #CLL pre-treated with a covalent #BTK inhibitor, which she shared at the 2023 European Hematology Association #EHA Congress. https://t.co/VjSeY9T9Qm https://t.co/DF0kMLaG55
-
-
Mashup Score: 0Future Potential of Noncovalent BTK Inhibitor Therapy for Patients With Chronic Lymphocytic Leukemia - 7 month(s) ago
Susan M. O’Brien, MD, discusses the possible applications of pirtobrutinib, a noncovalent BTK inhibitor, for the treatment of patients with CLL.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0BTK Inhibitors in Combination With Other Therapies as First-Line Treatment for Patients With Mantle Cell Lymphoma - 7 month(s) ago
At the 2023 EHA Congress, Vincent Ribrag, MD, participated in a debate regarding if BTK inhibitors should be combined with other therapies such as bendamustine and rituximab as first-line treatment for mantle cell lymphoma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At the 2023 European Hematology Association #EHA Congress, Vincent Ribrag, MD, debated whether #BTK inhibitors should be combined with other therapies, such as #bendamustine and #rituximab, as first-line treatment for patients with #MCL. https://t.co/aAvq27JhxU @EHA_Hematology https://t.co/72lsjSd0Kd
-
-
Mashup Score: 0Non-High-Dose Cytarabine Chemotherapy Plus BTK Inhibitor Treatment Shows Promise Among Patients With Newly Diagnosed Mantle Cell Lymphoma - 7 month(s) ago
According to a real-world multicenter study, non-high-dose cytarabine chemotherapy plus BTK inhibitor treatment may be a valuable first-line therapeutic option for younger patients with mantle cell lymphoma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0HOME - Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors - 7 month(s) ago
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the…
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
At the 2023 #GDUHem Meeting, John Allan, MD, discusses the current treatment landscape for #CLL, focusing on the use of #BTK inhibitors in combination therapy among patients. Learn more: https://t.co/TlsgGz2V8C @GreatDebatesCME @WeillCornell https://t.co/sCJcrcboZx